Skip to content
DataLookout
Menu

NCT07321652

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 224 → 261 locations
  2. Notable Eligibility criteria expanded, about 32 words
    • Trial sites expanded: 210 → 224 locations
    • Study description revised
  3. Minor Trial sites expanded: 182 → 210 locationsv5
  4. Minor Trial sites expanded: 152 → 182 locationsv4
  5. Minor Trial sites expanded: 141 → 152 locationsv3
  6. Notable Recruitment opened
    • Start date changed from estimate of Jan 15, 2026 to Apr 30, 2026
    • Trial sites expanded: 0 → 141 locations
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression free survival (PFS)
Timeframe: From initial randomization date until the earlier of disease progression or death from any cause, up to 10 years

Arms and interventions

Arm 1 (zanubrutinib)Active comparator

Patients receive zanubrutinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo restaging starting at cycle 15 day 1. Patients with at least partial remission continue therapy as described above. Patients with progressive disease proceed to follow up. Patients undergo CT scan, bone marrow aspiration and blood sample collection throughout the study.

Arm 2 (zanubrutinib and sonrotoclax)Experimental

Patients receive zanubrutinib PO BID on days 1-28 of each cycle. Starting cycle 4 day 1 patients also receive sonrotoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo restaging starting at cycle 15 day 1. Patients with undetectable MRD and a response of PR, PR-L, CR, CCR or CRi stop therapy at cycle 15 day 28 and proceed to follow up. Patients with detectable MRD and an objective response to therapy are re-randomized to arm 2B or arm 2C. ARM 2B: Patients continue zanubrutinib PO BID sonrotoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for an additonal 12 cycles in the absence of disease progression or unacceptable toxicity. ARM 2C: Patients discontinue therapy starting at cycle 15 day 28 and proceed to follow up. Patients undergo CT scan, bone marrow aspiration and blood sample collection

Drugs: Zanubrutinib, Sonrotoclax

Procedures: Computed Tomography, Bone Marrow Aspiration, Biospecimen Collection

Other: Survey Administration

Sites

261 sites in 1 country